158 filings
Page 4 of 8
8-K
ib92qchyhyii sxsbue
31 Jul 17
Loxo Oncology Announces Acquisition of Highly Selective, Reversible BTK Inhibitor Program
12:00am
8-K
r995tfid
23 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
424B5
42cwk9wpm
15 Jun 17
Prospectus supplement for primary offering
12:00am
8-K
0j7wot zxc
15 Jun 17
Loxo Oncology Prices Follow-On Offering of Common Stock
12:00am
424B5
404tz
13 Jun 17
Prospectus supplement for primary offering
12:00am
S-3ASR
1e7mjpo
13 Jun 17
Automatic shelf registration
12:00am
8-K
sgima7vvkwsdvwpln
5 Jun 17
Regulation FD Disclosure
12:00am
8-K
1u6p5b5gzohdbvdvazl8
9 May 17
Results of Operations and Financial Condition
12:00am
DEFA14A
48k0 63cl2ajnhu
1 May 17
Additional proxy soliciting materials
12:00am
8-K
tmkvdof 753
21 Mar 17
Changes in Registrant's Certifying Accountant
12:00am
8-K
tjs8 mns87
7 Mar 17
Results of Operations and Financial Condition
12:00am
S-8
8jp7lyemampy
7 Mar 17
Registration of securities for employees
12:00am
8-K
d0qsall
5 Jan 17
Loxo Oncology Prices Follow-On Offering of Common Stock
12:00am
424B5
f5wdqtvcb0z9nqmy
5 Jan 17
Prospectus supplement for primary offering
12:00am
424B5
sxojhq6n4l2r16vhrr0g
4 Jan 17
Prospectus supplement for primary offering
12:00am
8-K
dgqiig1ty
19 Dec 16
Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update
12:00am
EFFECT
r06 rzil1c
16 Nov 16
Notice of effectiveness
12:00am